Progrès récents concernant les mécanismes immunitaires de la sclérose en plaques

Archelos, 2000, The role of B cells and autoantibodies in multiple sclerosis, Ann Neurol, 47, 694, 10.1002/1531-8249(200006)47:6<694::AID-ANA2>3.0.CO;2-W Bielekova, 2004, Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta, Proc Natl Acad Sci USA, 101, 8705, 10.1073/pnas.0402653101 Bitsch, 2000, Tumour necrosis factor alpha m RNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology, Glia, 29, 366, 10.1002/(SICI)1098-1136(20000215)29:4<366::AID-GLIA7>3.0.CO;2-Y Brosnan, 1995, Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species., Neurology, 45, S16, 10.1212/WNL.45.6_Suppl_6.S16 Cannella, 1995, The adhesion molecule and cytokine profile of multiple sclerosis lesions, Ann Neurol, 37, 424, 10.1002/ana.410370404 Carmody, 2002, Genomic scale profiling of autoimmune inflammation in the central nervous system: the nervous response to inflammation, J Neuroimmunol, 133, 95, 10.1016/S0165-5728(02)00366-1 Chabas, 2000, Rôle de l’autoimmunité dans la sclérose en plaques(Paris), Pathol Biol, 48, 25 Chabas, 2001, The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease, Science, 294, 1731, 10.1126/science.1062960 Ciccarelli, 2001, Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations, Neurology, 56, 926, 10.1212/WNL.56.7.926 Coles, 1999, Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis, Lancet, 354, 1691, 10.1016/S0140-6736(99)02429-0 Coles, 1999, Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis, Ann Neurol, 46, 296, 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-# Comabella, 1998, Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy, J Clin Invest, 102, 671, 10.1172/JCI3125 Comabella, 2005, Plasma osteopontin levels in multiple sclerosis, J Neuroimmunol, 158, 231, 10.1016/j.jneuroim.2004.09.004 Conférence de consensus. (2001). Rev Neurol, 157: 907-1192. Dalton, 2004, Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis, J Neurol, 251, 407, 10.1007/s00415-004-0332-4 De Groot, 1999, Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures, J Neuropathol Exp Neurol, 58, 174, 10.1097/00005072-199902000-00007 Dyment, 2004, Genetics of multiple sclerosis, Lancet Neurol, 3, 104, 10.1016/S1474-4422(03)00663-X Ebers, 1998, 3rd edition Mc Alpine's Multiple Sclerosis, Churchill Livingstone Fassbender, 1998, Increased release of interleukin-12p40 in MS: association with intracerebral inflammation, Neurology, 51, 753, 10.1212/WNL.51.3.753 Fontaine, 2000, Prédisposition génétique à la sclérose en plaques(Paris), Pathol Biol, 48, 87 Gallo, 1989, Tumor necrosis factor alpha (TNF alpha) and neurological diseases. Failure in detecting TNF alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours, J Neuroimmunol, 23, 41, 10.1016/0165-5728(89)90071-4 Gallo, 1989, Immune activation in multiple sclerosis: study of IL-2, s IL-2R, and gamma-IFN levels in serum and cerebrospinal fluid, J Neurol Sci, 92, 9, 10.1016/0022-510X(89)90171-8 Gallo, 1991, A longitudinal study on IL-2, s IL-2R IL-4 and IFN-gamma in multiple sclerosis CSF and serum, J Neurol Sci, 101, 227, 10.1016/0022-510X(91)90050-H Giuliani, 2003, Vulnerability of human neurons to T cell-mediated cytotoxicity, J Immunol, 171, 368, 10.4049/jimmunol.171.1.368 Gomes, 2003, Decreased levels of CD95 and caspase-8 m RNA in multiple sclerosis patients with gadolinium-enhancing lesions on MRI, Neurosci Lett, 352, 101, 10.1016/j.neulet.2003.08.030 Hartung, 1995, Circulating adhesion molecules and inflammatory mediators in demyelination: a review., Neurology, 45, S22, 10.1212/WNL.45.6_Suppl_6.S22 Hauser, 1990, Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6, Neurology, 40, 1735, 10.1212/WNL.40.11.1735 Hofman, 1986, Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain, J Immunol, 136, 3239, 10.4049/jimmunol.136.9.3239 Hofman, 1989, Tumor necrosis factor identified in multiple sclerosis brain, J Exp Med, 170, 607, 10.1084/jem.170.2.607 Hvas, 1997, Perivascular T cells express the pro-inflammatory chemokine RANTES m RNA in multiple sclerosis lesions, Scand J Immunol, 46, 195, 10.1046/j.1365-3083.1997.d01-100.x Ibrahim, 2001, Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis., Brain, 124, 1927, 10.1093/brain/124.10.1927 Ichioka, 1988, Anti-galactocerebroside antibodies in human cerebrospinal fluids determined by enzyme-linked immunosorbent assay (ELISA), Neurochem Res, 13, 203, 10.1007/BF00971533 Ishizu, 2005, Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis., Brain, 128, 988, 10.1093/brain/awh453 Kappos, 2000, Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial, Nat Med, 6, 1176, 10.1038/80525 Kinkel, 1997, Rapid neurological deterioration in a patient with multiple sclerosis treated with systemic interleukin-2 and interferon-alpha 2b for metastatic renal cell carcinoma, J Neurol Neurosurg Psychiatry, 62, 100, 10.1136/jnnp.62.1.100 Kleine, 2003, Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8., Brain Res Bull, 61, 327, 10.1016/S0361-9230(03)00096-0 Koike, 2003, Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis, J Neuroimmunol, 139, 109, 10.1016/S0165-5728(03)00155-3 Kraus, 2002, Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis, Acta Neurol Scand, 105, 300, 10.1034/j.1600-0404.2002.1o199.x Kuhlmann, 2002, Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, Brain, 125, 2202, 10.1093/brain/awf235 Lalive, 2005, Serum neuronal toxicity in multiple sclerosis, Neurology, 64, 270 Link, 1994, Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis, Ann Neurol, 36, 379, 10.1002/ana.410360309 Lock, 2002, Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis, Nat Med, 8, 500, 10.1038/nm0502-500 Lucchinetti, 2000, Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination, Ann Neurol, 47, 707, 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q Maimone, 1991, Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis, J Neuroimmunol, 32, 67, 10.1016/0165-5728(91)90073-G Matejuk, 2002, Evaluation of the effects of 17beta-estradiol (17beta-e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray, Endocrinology, 143, 313, 10.1210/en.143.1.313 Matejuk, 2003, CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis, J Neurosci Res, 73, 667, 10.1002/jnr.10689 Matthews, 2004, An update on neuroimaging of multiple sclerosis, Curr Opin Neurol, 17, 453, 10.1097/01.wco.0000137537.06986.b0 Mc Donald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, 50, 121, 10.1002/ana.1032 Mc Manus, 1998, MCP-1 MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study, J Neuroimmunol, 86, 20, 10.1016/S0165-5728(98)00002-2 Menge, 2005, The anti-galactocerebroside antibody response as a novel biomarker for staging multiple sclerosis, Neurology, 64, 270 Miller, 2003, A controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 348, 15, 10.1056/NEJMoa020696 Mycko, 2003, c DNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity., Brain,, 126, 1048, 10.1093/brain/awg107 Navikas, 1996, Increased interleukin-6 m RNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis, J Neuroimmunol, 64, 63, 10.1016/0165-5728(95)00155-7 Nguyen, 2000, Detection of cytochrome P450 and other drug-metabolizing enzyme m RNAs in peripheral blood mononuclear cells using DNA arrays, Drug Metab Dispos, 28, 987 Nicot, 2003, Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction, Brain, 126, 398, 10.1093/brain/awg041 O’Connor, 2005, High-throughput analysis of autoantibodies recognizing myelin antigens in acute disseminated encephalomyelitis., Neurology,, 64, 417 O’Connor, 2004, Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects, Neurology, 62, 2038, 10.1212/01.WNL.0000128136.79044.D6 O’Regan, 2000, Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks [In Process Citation], Immunol Today, 21, 475, 10.1016/S0167-5699(00)01715-1 Olerup, 1991, HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation, Tissue Antigens, 38, 1, 10.1111/j.1399-0039.1991.tb02029.x Panitch, 1987, Exacerbations of multiple sclerosis in patients treated with gamma interferon, Lancet, 1, 893, 10.1016/S0140-6736(87)92863-7 Panitch, 1987, Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system, Neurology, 37, 1097, 10.1212/WNL.37.7.1097 Polman, 2003, New and emerging treatment options for multiple sclerosis, Lancet Neurol, 2, 563, 10.1016/S1474-4422(03)00505-2 Ramanathan, 2001, In vivo gene expression revealed by c DNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects, J Neuroimmunol, 116, 213, 10.1016/S0165-5728(01)00308-3 Rastetter, 2004, Rituximab: expanding role in therapy for lymphomas and autoimmune diseases, Annu Rev Med, 55, 477, 10.1146/annurev.med.55.091902.104249 Rieckmann, 1995, Semi-quantitative analysis of cytokine gene expression in blood and cerebrospinal fluid cells by reverse transcriptase polymerase chain reaction. Res Exp Med (Berl), 195, 17 Robinson, 2003, Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis, Nat Biotechnol, 21, 1033, 10.1038/nbt859 Robinson, 2003, Genomic and proteomic analysis of multiple sclerosis, Opinion. Curr Opin Immunol, 15, 660, 10.1016/j.coi.2003.09.015 Rodriguez -Sainz Mdel, 2002, Th1&sol;Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis, Eur Cytokine Netw, 13, 110 Rosenbluth, 1997, Spinal cord dysmyelination induced in vivo by Ig M antibodies to three different myelin glycolipids, Glia, 19, 58, 10.1002/(SICI)1098-1136(199701)19:1<58::AID-GLIA6>3.0.CO;2-6 Rosenbluth, 1999, Antibody-mediated CNS demyelination: focal spinal cord lesions induced by implantation of an Ig M anti-galactocerebroside-secreting hybridoma, J Neurocytol, 28, 397, 10.1023/A:1007021916210 Selmaj, 1991, Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions, J Clin Invest, 87, 949, 10.1172/JCI115102 Selvaraju, 2004, Osteopontin is upregulated during in vivo demyelination and remyelination and enhances myelin formation in vitro, Mol Cell Neurosci, 25, 707, 10.1016/j.mcn.2003.12.014 Sharief, 1991, The relationship of interleukin-2 and soluble interleukin-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis, J Neuroimmunol, 32, 43, 10.1016/0165-5728(91)90070-N Sharief, 1992, In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis, J Neuroimmunol, 38, 27, 10.1016/0165-5728(92)90087-2 Steinman, 2001, Multiple sclerosis: a two-stage disease, Nat Immunol, 2, 762, 10.1038/ni0901-762 Steinman, 2003, Response to Comment on “The influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease“, Science Mar, 21, 1845b Sturzebecher, 2003, Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis., Brain, 126, 1419, 10.1093/brain/awg147 Stuve, 2003, Statins as potential therapeutic agents in neuroinflammatory disorders, Curr Opin Neurol, 16, 393, 10.1097/00019052-200306000-00021 Trapp, 1998, Axonal transection in the lesions of multiple sclerosis, N Engl J Med, 338, 278, 10.1056/NEJM199801293380502 Villar, 2002, Intrathecal Ig M synthesis predicts the onset of new relapses and a worse disease course in MS, Neurology, 59, 555, 10.1212/WNL.59.4.555 Villar, 2005, Intrathecal synthesis of oligoclonal Ig M against myelin lipids predicts an aggressive disease course in MS, J Clin Invest, 115, 187, 10.1172/JCI22833 Vogt, 2003, Elevated osteopontin levels in active relapsing-remitting multiple sclerosis, Ann Neurol, 53, 819, 10.1002/ana.10606 Vogt, 2004, Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients, J Neuroimmunol, 155, 155, 10.1016/j.jneuroim.2004.06.007 Wandinger, 2001, Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes, Ann Neurol, 50, 349, 10.1002/ana.1096 Whitney, 1999, Analysis of gene expression in mutiple sclerosis lesions using c DNA microarrays, Ann Neurol, 46, 425, 10.1002/1531-8249(199909)46:3<425::AID-ANA22>3.0.CO;2-O Whitney, 2001, Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions, J Neuroimmunol, 121, 40, 10.1016/S0165-5728(01)00438-6 Windhagen, 1995, Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions, J Exp Med, 182, 1985, 10.1084/jem.182.6.1985 Woodroofe, 1993, Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization, Cytokine, 5, 583, 10.1016/S1043-4666(05)80008-0 Youssef, 2002, The HMG-Co A reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease, Nature, 420, 78, 10.1038/nature01158 Yu, 1996, A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease, J Exp Med, 183, 1777, 10.1084/jem.183.4.1777